Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05826171
Other study ID # 23-088
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 6, 2023
Est. completion date May 31, 2025

Study information

Verified date May 2024
Source Teachers College, Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PRIME-Ataxia is a randomized controlled trial that aims to determine the feasibility and efficacy of an 8-week telehealth intervention of high intensity aerobic exercise prior to balance training compared to an 8-week telehealth intervention of low intensity exercise prior to balance training in people with spinocerebellar ataxias (SCAs). The investigators additionally aim to explore changes in motor skill learning on a novel motor skill task in a sub-group of participants pre and post intervention.


Description:

The PRIME-Ataxia randomized controlled trial involves 2 groups of participants (n=20). One group (high intensity exercise + balance) will receive high intensity aerobic exercise followed by balance training, and another group (low intensity exercise + balance) will receive low intensity exercise (stretching, warm up exercises) followed by balance training. Both groups will undergo four remote assessments (2 baseline assessments, a mid-intervention assessment, and a post-intervention assessment). A subset of individuals (n=12) from both groups will undergo an in-person assessment on a novel motor task, along with digital posturography assessment of standard functional assessments of mobility and balance at baseline 1 (week 0), and post-intervention (week 16).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date May 31, 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Between the ages of 18 to 85 years 2. Genetically confirmed diagnosis of SCA1, 2, 3, 6, and 7 3. Scale for Ataxia Rating and Assessment (SARA) score between 8-25/40, capturing mild-moderate disease 4. Able to walk with/without assistive device 5. Successful completion of Physical Activity Readiness Questionnaire (PAR-Q) to confirm no medical contraindications to exercise 6. Care partner availability during assessments and/or intervention pending balance scores Exclusion Criteria: 1. Severe non-ataxic motor symptoms such as dystonia, tremor, or Parkinsonism, measured by Inventory of Non-Ataxia Signs (INAS) 2. Peripheral sensory loss (as confirmed with monofilament or clinical proprioceptive testing) 3. Severe visual complications associated with ataxia (i.e., Spontaneous nystagmus, retinal or optic nerve involvement, especially in SCA7) defined as as have a score on the Snellen Visual Acuity test = 20/200 - 20/400, OR a visual field of 20 degrees of less. 4. Musculoskeletal injury that would prevent participation in an exercise program 5. Other concurrent disease of the cerebellum (e.g. stroke, multiple sclerosis) 6. Cardiac/pulmonary conditions that would affect participants ability to participate exercise program 7. Currently engaged in >3 week moderate-high intensity aerobic exercise and/or balance training

Study Design


Intervention

Behavioral:
High-Intensity Aerobic Exercise Prior to Balance Training
20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
Low-Intensity Exercise Prior to Balance Training
20-30 minutes of light intensity "warm-up" type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the "warm-up" exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome. Both groups are matched for time and frequency of intervention components.

Locations

Country Name City State
United States Teachers College, Columbia University New York New York

Sponsors (1)

Lead Sponsor Collaborator
Teachers College, Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Scale for Assessment and Rating for Ataxia Clinical rating scale for severity of ataxia symptoms. This is an 8-item clinical performance based scale, which individuals are graded according to total ataxia severity. Total scores can range from 0 (no ataxia) to 40 (most severe ataxia). Scores are based on performance of the following tasks: 1) Gait, 2) Stance, 3), Sitting, 4) Speech Disturbance, 5) Finger Chase, 6) Nose-Finger Test, 7) Fast alternating hand movements, 8) Heel-shin slide. For the purpose of this study, we will be performing a validated modified version of the SARA, referred to as the SARAHome. The SARAHome is comprised of the first four items and item 6 from the original SARA Scale (Gait, Stance, Walking, Speech, and Nose-Finger Test) and it will be administered via telehealth. Baseline, Post-Intervention (4 months)
Primary Change in Cerebellar Cognitive Affective Syndrome Scale The Cerebellar Cognitive Affective Syndrome Scale (CCAS) was developed as a bedside quick screen for Cerebellar Cognitive Affective Symptom (also referred to as Schmalmann's Syndrome). The CCAS is a 10-item scale of cognitive and neuropsychiatric tests detailing executive function, working and verbal memory, language, visuospatial function, abstract reasoning, behavior and affect. Two scores are reported; a raw score ranging from 0 (severe cognitive impairment) to 120 points (no cognitive impairment), as well as a Pass/Fail marker for each of the 10 items on the scale. 1 fail is considered as possible cerebellar cognitive affective symptom, 2 fails are considered probable, and 3 fails are considered clinically definite. Baseline, Post-Intervention (4 months)
Primary Change in Patient Reported Outcome Measure for Ataxia Patient reported outcome measure for people with ataxia. The test was developed to assess 3 domains (physical, activities of daily living, mental health) and 14 subdomains. It has been proven to be valid and reliable against measures of motor ataxia, mental health, and quality of life. The original Patient Reported Outcome Measure for Ataxia has 70 questions, and records a total score out of 280 possible points. For the purpose of this trial, we will use the Short-Form version of this assessment which asks 10 questions, and it scored out of a total of 40 possible points. Baseline, Post-Intervention (4 months)
Secondary Activities Specific Balance Scale (ABC) Patient reported outcome evaluating the balance confidence of a participant in performing a variety of activities without losing balance or experiencing a state of unsteadiness. Participants are asked to rank their perceived balance confidence on a scale of 0% (no balance confidence) to 100% (high balance confidence). All scores are summed, and averaged for a total overall estimate of balance confidence. Baseline, Post-Intervention (4 months)
Secondary Digital Biomarker of Static Posturography Participant will perform a series of static standing postures and postural sway will be recorded with a smart phone app, and/or inertial measurement units. Measure of postural sway will be recorded (higher values are worse outcomes). Baseline, Post-Intervention (4 months)
Secondary Digital Biomarker of Dynamic Posturography Participant will perform a walking test which will be recorded with a smart phone app, and/or inertial measurement units. Measure of postural sway will be recorded (higher values are worse outcomes). Baseline, Post-Intervention (4 months)
Secondary Motor Adaptation Prism Adaptation with finger targeting to touchscreen. Performed in a sub-set of participants for this trial. Baseline, Post-Intervention (4 months)
Secondary Neurological Quality of Life Self report of health related quality of life for people with neurological conditions. The measure that will be used in this trial is a short-form assessing social or functional roles and abilities. 8 questions with 5-item Likert response, higher score is better outcome. Baseline, Post-Intervention (4 months)
Secondary Patient Global Impression of Change Self-report measure that assesses a participants thoughts or beliefs about the efficacy of treatment. The Patient Global Impression of Change scale is a 7 point scale depicting a patient's rating of overall improvement, score 1-7, higher score is better. Baseline, Post-Intervention (4 months)
Secondary Acceptability Questionnaire Short open-ended questionnaire to assess the acceptability of the intervention. These open-ended questions will be analyzed qualitatively. Baseline, Post-Intervention (4 months)
See also
  Status Clinical Trial Phase
Completed NCT00992771 - Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Phase 2
Completed NCT01096082 - Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Phase 2/Phase 3
Active, not recruiting NCT03701399 - Troriluzole in Adult Subjects With Spinocerebellar Ataxia Phase 3
Active, not recruiting NCT04229823 - Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
Active, not recruiting NCT04419974 - Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
Terminated NCT05490563 - STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia Phase 2/Phase 3
Withdrawn NCT04301284 - Study of CAD-1883 for Spinocerebellar Ataxia Phase 2
Withdrawn NCT01096095 - Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3 Phase 2
Active, not recruiting NCT04268147 - Instrumented Data Exchange for Ataxia Study
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT04399265 - Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3 N/A
Completed NCT03885167 - Identification of Biomarkers in Spinocerebellar Ataxia 3
Terminated NCT05160558 - A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 Phase 1
Recruiting NCT05822908 - A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD Phase 1/Phase 2
Not yet recruiting NCT03378414 - Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia Phase 2
Completed NCT05502432 - Repetitive Transcranial Magnetic Stimulation in SCA3 Patients N/A
Recruiting NCT04714307 - Neuropsychiatry and Cognition in SCA3/MJD
Recruiting NCT05557786 - Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
Recruiting NCT01060371 - Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias